



Life Sciences Ideas to Action Life Sciences Forum - Speaker Bios November 13th, 2024

**Johnson & Johnson
Innovative Medicine**



BLG
Borden Ladner Gervais

A science mindset.



stryker



moderna



LEADERS CIRCLE

3 SIXTY
PUBLIC AFFAIRS

8:00-8:30am | Registration & Networking Breakfast



8:30-8:40am | Welcome

8:40- 9:10am | Keynote Address - 15 Years of Impact: Reflecting on the Journey and Igniting the Future of Canada's Life Sciences



Zayna Khayat, In-house Futurist, Life Sciences & Healthcare, Deloitte Canada

Zayna Khayat is the in-house health futurist with Deloitte Canada's Healthcare and Life Sciences practice. She is also the adjunct faculty in the Health Sector Strategy stream at the Rotman School of Management at the University of Toronto, where she instructs a course in healthcare innovation and partnerships in the health MBA program. Zayna is a Growth Advisor at Teladoc Health in Canada and advises a few emerging health startups. Zayna previously led the Futures team with national home healthcare and aging social enterprise, SE Health, as their Future Strategist. Dr. Khayat was previously the lead of health system innovation at MaRS Discovery District, a health innovation hub in Toronto, Canada. In 2017 she was seconded to the RShape Innovation Centre at Radboud university medical centre in the Netherlands. Zayna completed her Ph.D. in diabetes research from the University of Toronto (2001), followed by a career in strategy consulting, including as a principal in the healthcare practice of The Boston Consulting Group (BCG). She currently resides in Toronto with her husband and three children and is proficient in French and Arabic languages (and a bit of Dutch!).

9:10–10:10am | Debate Panel: Ontario's Opportunities in the Life Sciences Sector



Moderator: Rachel Simeon, Assistant Deputy Minister, Ontario Ministry of Economic Development, Job Creation and Trade

Rachel Simeon is the Assistant Deputy Minister, Innovation and Economic Partnerships division at the Ministry of Economic Development, Job Creation and Trade, responsible for strengthening Ontario's innovation ecosystem, supporting regional economic development, and engagement with Ontario-based companies in ICT and life sciences. Rachel and her team led the work to develop the Life Sciences Strategy, Phase 2, which was released on October 15, 2024. Rachel has worked in numerous ministries across her 25+ year career with the Ontario Public Service, including Treasury Board Secretariat, the Ministry of Colleges and Universities, the Ministry of Municipal Affairs and Housing, and Cabinet Office. Rachel holds an Honours B.A in Political Science from the University of Toronto and a Master of Public Policy from University College London.



Maura Campbell, President & CEO, Ontario Bioscience Innovation Organization (OBIO)

Dr. Maura Campbell is the President and CEO of OBIO®, a not-for-profit, membership-based organization dedicated to advancing health technology innovation and commercialization. Dr. Campbell has more than 30 years of experience in all key areas of biotech, including private and public companies, universities and research institutes, and government-funded public sector research organizations. With expertise in technology transfer and commercialization of intellectual property, Dr. Campbell has held various roles in senior management, most recently as the Vice-President of Intellectual Property and Contracts for Turnstone Biologics, which recently went public on the NASDAQ. Previously, Dr. Campbell served as: Director, Intellectual Property at VBI Vaccines; Research Program Manager, and Manager of Technology Transfer & Commercialization at the Ottawa Hospital Research Institute; Director of Intellectual Property for PainCeptor Pharma Corporation; and Manager of Technology Transfer at the Institute for Robotics and Intelligent Systems National Centre of Excellence. Dr. Campbell has also served as an IP consultant to a number of Canadian start-ups including Neurochem, Conjuchem, Aonix, AMRIC and Sussex Research Labs. Dr. Campbell received a Ph.D. in biochemistry from the University of Ottawa, and an M.Sc. and a B.Sc. in biochemistry from Queen's University in Kingston. Dr. Campbell is the Vice-Chair of Ontario's Life Sciences Council, supporting a plan to make Ontario a top hub for innovation growth and life sciences investment. She also serves as a board member for FACIT (a business accelerator and investor established by the Ontario Institute for Cancer Research), SPEC Labs and Capital BioVentures (federally funded life science incubators in Toronto and Ottawa) and Intellectual Property Ontario (a provincial agency providing IP support for Ontario innovators).



Ivy Parks, President, BD Canada

Ivy Parks is the President of BD-Canada (Becton, Dickinson, and Company), a leading global and Canadian medical technology company. During her two-decade tenure at BD-Canada, Ivy has developed an insightful perspective of the Canadian healthcare landscape, particularly in acute care, alternate care, pharmacy, and laboratory services. Renowned for her market insight and collaborative approach, Ivy works closely with medical associations, partners, and health systems across Canada to leverage medical technology as a solution to some of the biggest healthcare challenges. Her strategic direction has strengthened BD-Canada's role in addressing these challenges, ensuring the company remains a pivotal player and partner in the medical technology landscape. Under Ivy's leadership, BD-Canada has continued to thrive, with a focus on innovation, health system resilience, and health equity. Before assuming her current role, Ivy served as Vice President for the Integrated Diagnostic Solutions (IDS) business. During this time, she worked with federal and provincial governments and led her team to deliver millions of PCR tests and rapid point-of-care tests using the BD Veritor™ Plus System to Canadians in response to the COVID-19 pandemic. Ivy is a member of Medtech Canada's Board of Directors and an active member of the Corporate Advisory Council with the Canadian College of Health Leaders. Her contributions significantly shape the dialogue around medical technology and patient care. Ivy also holds an Honours Bachelor of Science degree from Western University in London, Ontario.



Peter van der Velden, Founder and Managing General Partner, Lumira Ventures

Peter is the Managing General Partner of Lumira Ventures, Canada’s largest and most active dedicated life sciences venture capital investor. Peter is a highly experienced venture capitalist who for the past 31 years has been building innovative, technology-centric companies from start-ups to expansion. In 2005 he was hired as CEO of MDS Capital Corp. and in the following two years he led the restructuring, subsequent buyout and ultimately the re-branding and repositioning of the firm as Lumira Ventures. During his tenure the firm has raised 5 funds, including raising more than C\$350 million for two funds in 2021 (Fund IV is the largest dedicated life sciences fund ever raised by a domestic Canadian VC manager). Via those funds, the Lumira team have backed dozens of transformative NA-based healthcare companies that have delivered more than 50 approved therapies for patients, generated significant cost savings for healthcare systems and produced significant returns for the investors in Lumira funds.

Peter is President and Chairman of the Canadian Venture and Private Equity Association (CVCA) where he led the rebuilding and re-positioning of the organization in parallel with supporting its role in the development and implementation of key provincial and federal initiatives (including the Venture Capital Action Plan) to rebuild and revitalize the venture capital industry in Canada. In addition to working with Federal and Provincial governments on policy matters related to healthcare innovation, Peter has represented the Canadian venture industry at global venture capital congresses in Europe, Asia and the Middle East. Peter is also a very active volunteer in the community and a frequent lecturer at universities and conferences on themes related to venture capital, innovation and healthcare.

In 2017, Peter led the launch of the firm’s philanthropic giving strategy. To date this has included a first in Canada donation of “Fund Carry” to 12 leading Canadian healthcare foundations, the “Double Bottom Line Challenge” to support more than 35 charities and businesses negatively impacted by Covid-19, and most recently the establishment of the Lumira Foundation to address the firm’s longer term and ongoing philanthropic initiatives. In recognition of the outstanding contributions made throughout his career with respect to serving to advance excellence in the Canadian private capital industry, in 2023 the CVCA awarded him the Barry Gekiere Lifetime Legacy Award.

Peter holds degrees from the Schulich School of Business (MBA finance and policy) and Queen’s University (M.Sc. (pathology), B.Sc. (honours life sciences)).


10:10-10:30am | Morning Networking Break

10:30- 11:30am | Panel 1 – Life Sciences Thought Leadership Panel



Moderator: Jason Field, President & CEO, Life Sciences Ontario

Jason Field is the President and CEO of Life Sciences Ontario (LSO), the industry voice for the life sciences sector in Ontario. LSO is a member-driven organization that represents and promotes the province’s vibrant and diverse life sciences sector. LSO collaborates with governments, academia, industry and other life science organizations in Ontario and across Canada to promote and encourage commercial success throughout this diverse sector. Jason obtained his PhD in Chemistry from the University of Massachusetts and his undergraduate degree from the University of Waterloo. Following graduate school, Jason returned to Ontario and worked in the pharmaceutical industry as a research scientist developing scalable manufacturing processes of active pharmaceutical ingredients. In 2007, he joined the Ministry of Economic Development and Trade (MEDT)



where he led a team of senior advisors dedicated to growing Ontario's life sciences and information and communication technologies (ICT) sectors. During his time at MEDT, Jason was integral to the development of a number of strategic policy initiatives and spearheaded negotiations with several major ICT and life sciences companies that resulted in significant new investments in the province. Jason joined LSO as Executive Director in October, 2011 and was appointed as President and CEO in April, 2014.



Andrew Casey, President & CEO, BIOTEC Canada

Andrew Casey became president and CEO of BIOTEC Canada in August, 2012. In his role as President & CEO of BIOTEC Canada Andrew is responsible for the strategic operations of the Association which represents Canada's biotechnology sector. As the head of BIOTEC Canada, he is the lead spokesperson for Canada's biotechnology industry communicating on the industry's behalf with government, regulators, international bodies, media and the Canadian public. Prior to joining BIOTEC Canada, Andrew served from

2004-2012 as Vice President, Public Affairs and International Trade with the Forest Products Association of Canada.



Nicole DeKort, President & CEO, Medtech Canada

Nicole DeKort is the President & CEO of Medtech Canada – the industry association representing Canada's Medical Technology Companies – pursuing opportunities to demonstrate the value of innovative medical technology to government, stakeholders, and key partners in the health care system. She previously served for 6 years at the Vice-President of Government Affairs: Federal and Ontario for Medtech Canada, and another 4 years as the Vice-President of Ontario & Marketing for Medtech Canada, overseeing Ontario government relations and national marketing programs for the association. Prior to joining Medtech Canada, Nicole has a 15-year background in politics

and government in a diverse portfolio of roles. Nicole's last role in government prior to joining Medtech Canada was serving as the Executive Director of Strategic Planning for the then Minister of Health and Long-Term Care. Nicole served for 5 years on the Board of Directors for Yellow Brick House, which provides shelter and support services for abused families and victims of gender-based violence in York Region. She also currently serves on the Board of Directors for Life Sciences Ontario



Bettina Hamelin, President, Innovative Medicines Canada (IMC)

Bettina Hamelin, PharmD, EMBA, is a globally renowned researcher and esteemed life sciences executive, who brings over 30 years of experience in academia, industry, and not-for-profit organizations to her current role as President of Innovative Medicines Canada (IMC). In this role, Dr. Hamelin is dedicated to enhancing access to innovative medicines for Canadians, while advancing Canada's position as an attractive destination for life sciences investments, high-value jobs, and new clinical trials. Driven by her unwavering commitment to improving the health and well-being of all Canadians, Dr. Hamelin firmly believes collaboration and

partnership are essential to the future of healthcare innovation in Canada. Having acquired an Executive MBA in Healthcare from the Sauder School of Business at the University of British Columbia, she is uniquely positioned to work alongside health system stakeholders to find novel solutions to complex challenges. Prior to joining IMC, Dr. Hamelin was the President and CEO of Ontario Genomics for over six transformative years. Here, she not only established the organization as Canada's preeminent force in engineering biology on the world stage, but also cultivated an ecosystem that was conducive to the



development and commercialization of cutting-edge Canadian innovations. Dr. Hamelin's illustrious career includes serving as the VicePresident of Research Partnerships at the Natural Sciences and Engineering Research Council of Canada (NSERC), where she led a 130-member team to spearhead a robust research and innovation investment strategy. She also held pivotal leadership roles at BioChem Pharma and Pfizer Inc., pioneering novel publicprivate partnership models that propelled research and innovation forward, and was a tenured professor at Université Laval. Dr. Hamelin is fluently trilingual and holds a Doctor of Pharmacy degree from the University of Kentucky, US. With her wealth of expertise, purpose-driven leadership, and passion for driving positive change in the pharmaceutical, health, and life sciences sectors, Dr. Hamelin stands as a trusted leader, poised to make enduring contributions to the health of Canadians and the vibrancy of Canada's research and innovation ecosystems.



Pierre Petelle, President & CEO, CropLife Canada

Pierre Petelle is the president and CEO of CropLife Canada, the trade association that represents the Canadian manufacturers, developers and distributors of pest control products and plants with novel traits. Pierre joined CropLife Canada in 2008 and is now responsible for the strategic direction and leadership of the association. CropLife Canada's goals include improving public confidence in our members' technologies, facilitating a positive regulatory environment, ensuring proper stewardship of our industry's products and building collaborative stakeholder relationships. Prior to joining CropLife Canada, Pierre worked in the policy office at Health Canada's Pest Management

Regulatory Agency where he worked on a wide range of issues relevant to Canada's plant science industry. Pierre holds degrees from Carleton University and the University of Guelph.

11:30am-12:30pm | Panel 2 – Building and Strengthening Canadian Anchor Companies: Challenges and Opportunities



Moderator: Parimal Nathwani, President & CEO, Toronto Innovation Acceleration Partners (TIAP)

A highly regarded life sciences industry leader and advocate with strong relationships across the academic and health research community, global industry, and investors, Parimal Nathwani has been with Toronto Innovation Acceleration Partners (TIAP) since its inception in 2008, first serving as Vice President and subsequently taking on the role of President and CEO in 2020. Parimal brings to TIAP more than 25 years of experience advancing health innovation including forming and scaling innovative new life sciences companies. His expertise includes technology transfer, intellectual property management, technology development, corporate finance, business development, alliance management and operations. Parimal has been actively involved in launching and managing more than a dozen start-up companies with activities such as raising early-stage capital, establishing strategic partnerships, recruiting management and advisors, and driving in- and out-licensing activities. Under Parimal's leadership, TIAP has launched impactful programs such as LAB150, a collaboration with global companies Evotec SE and Amgen that has brought considerable new financial and mentorship resources to Ontario's life sciences ecosystem to accelerate early-stage drug development. Before joining TIAP, Parimal was a healthcare analyst with a boutique investment bank where he conducted equity research on publicly traded biotechnology companies in Canada and the U.S. He also led commercialization activities at BC Women's and Children's Hospital as part of his role at the University of British Columbia's Industry Liaison Office. Parimal started his career as a research scientist at a start-up biotechnology company involved in drug



discovery targeting ABC Transporters. Parimal is currently Chair of Vasomune Therapeutics, a Director of Fibrocor Therapeutics, TRIUMF Innovations, and the Nanomedicine Innovation Network, and an Observer on the Boards of Zucara Therapeutics and Radiant Biotherapeutics. He received his MBA from Simon Fraser University and his M.Sc. from the University of British Columbia.



Christine Allen, Professor, University of Toronto

Dr. Christine Allen is a full professor at the University of Toronto (U of T) and an internationally recognized leader with more than 170 publications in drug formulation and development. She is a member of the Scientific Leadership Team of the Acceleration Consortium, a strategic initiative at the University of Toronto awarded \$200M in funding from the Canada First Research Excellence Fund. She has received numerous awards and is a distinguished fellow of prestigious societies including the American Institute for Medical and Biological Engineering, and the Canadian Academy of Health Sciences.

Christine is committed to the translation and commercialization of her research. She is a co-founder and CEO of Intrepid Labs Inc., a company that is accelerating pharmaceutical drug development through integration of AI, automation and advanced computing. She is also a co-founder and board member at Nanovista Inc. Her lab at U of T is deeply engaged in industry partnerships, playing a key role in advancing drugs from early-stage research to clinical trials.

Her leadership has been pivotal in several scientific societies, notably as President of the Controlled Release Society and the Canadian Society for Pharmaceutical Sciences. In academia, her roles have included the inaugural Associate Vice-President and Vice Provost Strategic Initiatives and Interim Dean of the Leslie Dan Faculty of Pharmacy.



Mike Canzoneri, President & CEO, Canadian Hospital Specialties


Mike joined CHS in January 2016, bringing 25 years of global strategic leadership in the medical industry. He has had several international senior leadership positions including Platform Leader Medication Workflow Systems, Commercial Leader Europe for Medical Surgical Systems and Director – Canada for BD Global. Prior to BD, Mike held senior management positions with Johnson & Johnson, Iovate Health Sciences and Baxter in the US, Australia, New Zealand and Canada. Mike has participated in and held varying positions on many boards within the health care industry, both domestically and internationally.



Diana Chan, Managing Director, BridgeGap Solutions Group

With over 20 years of experience in the medical device industry, Diana is a seasoned marketing leader dedicated to driving growth and innovation. She played a key role in MOLLI Surgical's journey, from building its brand presence and implementing growth strategies to its successful exit after three years of commercialization through acquisition by Stryker. Currently, she provides advisory and mentorship in the medtech space through BridgeGap Solutions Group, a consultancy she founded to support organizations with limited resources in business and market development. Diana has held executive positions at Medtronic, Bard, and Fresenius Medical Care. With broad market expertise and a proven track record of delivering innovative solutions, she was

honoured to be recognized as one of PR Daily's Top Women in Marketing for 2023. Passionate about health and wellness, Diana actively supports community causes like Princess Margaret Hospital Foundation's Ride to Conquer Cancer. As a proud alumna of the University of Notre Dame, she lives by the motto "Play like a Champion" every day.



Tamara Seales, President, Seaford Pharmaceuticals

Tamara Seales serves as the President of Seaford Pharmaceuticals, where she is recognized for her dynamic and forward-thinking leadership. She oversees the company's administration, finance, strategy, and marketing, and has been a key figure in Seaford's leadership for over 20 years. Tamara's academic background is distinguished, with a Bachelor of Commerce from York University and an MBA from the Schulich School of Business at the same institution.

In addition to her professional achievements, Tamara is known for her philanthropic efforts. She has championed Seaford Pharmaceuticals' charitable projects, including the creation of a pediatric clinic in Jamaica and significant contributions to disaster relief. She is also deeply involved in fundraising for women's health, cancer research, and brain health. Her leadership was particularly impactful during the challenges of the pandemic, where her strategic decisions ensured Seaford Pharmaceuticals' stability and growth. Under her guidance, the company has not only established key departments but also expanded its global presence through successful international partnerships. Tamara Seales' inspirational leadership and dedication to philanthropy continue to drive Seaford Pharmaceuticals and the broader pharmaceutical industry towards a more promising and equitable future.

12:30- 1:15pm | Buffet Lunch (Provided)

1:15- 2:15pm | Political Pundits Panel – How to Engage Government in a Strategic Way?



Moderator: Mark Smithyes, National Director, Life Sciences, Delphic Research

Mark is known as a transformational leader drawing on his experience from a 30+ year career in Life Sciences. Currently, Mark leads the Life Sciences Practice at Delphic Research. His extensive career includes various senior leadership positions in pharmaceutical and medical device multinationals like Novartis and Alcon as well as founding, running, and exiting a successful life sciences start-up venture. In 2017, Mark founded Janus Life Sciences Consulting to help other entrepreneurs drive their business success, focusing on seed and early-stage

fundraising, strategy, and commercialization.

Mark serves as an advisor for several funds and incubators including Genome Quebec, the Ontario Centre of Innovation, the University of Toronto's SpinUp, Sunnybrook Research Institute's Medventions, and Accelerating Clinical Trials Canada. He is on faculty at the University of Toronto's Master of Biotechnology program and Toronto Metropolitan University's Life Sciences Talent Accelerator. Mark is on the Board of Directors and is former Chair of Life Sciences Ontario. He holds an MBA from the Kellogg School of Management and the Schulich School of Business.



Jordan Lechnitz, Political Advisor, Curse of Politics

Jordan Lechnitz is a political advisor with two decades of experience in progressive political strategy, civil society and campaigns at the federal, provincial and municipal level. She spent ten years on Parliament Hill working in senior strategy positions for four Leaders of the New Democratic Party of Canada, including serving as Deputy Chief of Staff, overseeing policy development and handling issues management for the parliamentary caucus. Since 2020, Jordan has served as the Canada Program Manager for the Friedrich Ebert Stiftung, a German political foundation. She is a frequent media commentator on federal and provincial politics, and a regular on The Curse of Politics podcast. Jordan holds a master's degree in political science

from the University of Ottawa, and lives in Ottawa with her partner and two young children.



Sarah Letersky, Senior Vice President, Rubicon Strategy

Sarah Letersky is a Senior Vice President and National Health Practice lead at Rubicon Strategy. Rubicon Strategy is a government relations firm that advises companies and associations in health care, life sciences, energy, and more. Prior to joining Rubicon, Sarah worked at Queen's Park as a Director of Communications and Chief of Staff to various Ministers in the Ford Government.



Jason Lietaer, President, Enterprise Canada

Enterprise Canada President Jason Lietaer leads the firm's national and provincial public affairs practice, advising some of Canada's largest corporations and organizations. A regular guest commentator on public affairs broadcasts, Jason brings unique insight into the development of federal and provincial public policy. His demonstrated success lies in aligning the goals and objectives of clients with those of the government, creating

mutually beneficial outcomes. Jason boasts a proven track record of providing counsel to the former Prime Minister of Canada, federal and provincial cabinet ministers, as well as current and past premiers across various provinces in Canada.



Kim Wright, Principal, Wright Strategies

Since 2005, Kim Wright has provided senior public affairs counsel to national and international clients across multiple industries. Kim has engaged in public affairs campaigns across Canada at all three orders of government. Leveraging her deep knowledge of politics and public affairs, she founded Wright Strategies in 2018. Kim has built and executed successful public affairs engagements on a wide range of issues including public health,

infrastructure, technology, economic development, transportation, labour relations, and licensing frameworks. Throughout her career, she has developed a well respected, pan-partisan approach to government relations that allows her and her clients to achieve a trusted advisor status. Kim is best known as a municipal affairs expert; however, she frequently navigates complex interjurisdictional files. She has been involved in politics & campaigning since 1990.



Kim is a frequent media commentator on political issues. She regularly appears on the CBC, TVO, CP24, Global News, SiriusXM, and CPAC. Lindsay and her husband Todd, have 2 daughters, Emily and Kate, and live in Burlington, ON.

2:15-3:15pm | Panel 4 – Advancements in Life Sciences – Frontiers of Technology



Moderator: Philippa King, Assistant Vice President of Strategic Programs, Ontario Centre Innovation

Philippa King is the Assistant Vice President of Strategic initiatives at the Ontario Centre of Innovation (OCI), a not-for-profit organization that drives the development, adoption and commercialization of disruptive technologies across a range of sectors. Philippa has nearly 20 years of experience in championing innovation and company and economic growth. Since joining OCI she has spearheaded several large-scale strategic initiatives that have brought together industry, academia, investors and multiple levels of Government in areas such as AI, 5G, life sciences, cybersecurity, construction and advanced manufacturing. In her current role at OCI, Philippa leads the Strategic Programs team to deliver life sciences, digital modernization, critical technology and industry-academic support to Ontario small-medium-sized enterprises. She also heads up OCI's Ready for Market and Life Science Investment Funds. Philippa holds a M.Sc. and a Ph.D. degree in Chemistry from the University of East Anglia, UK and the Karlsruhe Institute of Technology, Germany respectively.



Melody Greaves, Manager, Business Strategy, Canadian Nuclear Isotope Council

Melody Greaves is the Manager of Business Strategy at the Canadian Nuclear Isotope Council – an independent not-for-profit advocacy organization consisting of representatives from various levels within the Canadian health sector, nuclear industry and research bodies, convened specifically to advocate for our country's role in the production of the world's isotope supply. In her role, Melody led the development of the organization's *Isotopes for Hope* campaign, an ambitious vision to double Canada's production of medical isotopes by 2030. She is now primarily responsible for the CNIC's major strategic initiatives and business expansion activities. Melody completed her undergraduate and graduate studies at Wilfrid Laurier University and holds a Master of Applied Politics degree in Public and Environmental Policy and a bachelor's degree in political science and French.



Alexis Sciuk, Global Medical, Digital Health Solutions, Pipeline Lead, Pfizer

Alexis Sciuk is the Pipeline Lead for Pfizer's Global, Medical Digital Health Team. She is focused on integrating medical digital capabilities into the core of the company's work. She is responsible for evaluating new medical grade, digital technologies, and health frameworks, ensuring Pfizer remains at the forefront of innovation in the digital health space. This includes assessing the potential impact and relevance of advancements, identifying opportunities for adoption and integration, and evaluating regulatory, market access and compliance aspects. Alexis is tasked with making sure Pfizer remains innovative, adaptable, and well-positioned to leverage digital advancements in improving health outcomes and delivering impactful digital health solutions to patients globally.



Doug Baumann , Chief Technology Officer , Vive Crop Protection

Doug Baumann is a chemist, engineer and recovering pilot who's been living the science life since 1999. His research career touched diverse fields such as solid-state physics, biochemical engineering, organic chemistry and biomedical engineering prior to shifting his focus to agriculture in 2011, when he joined Syngenta Crop Protection at their Honeywood Research Facility. Dr. Baumann undertook a variety of roles at Syngenta, always at the interface of chemistry, biology and engineering. In 2022 Doug joined Vive Crop Protection as Vice-President, Product Development and since 2023 has served as Vive's Chief Technology Officer. Vive is a pioneer in the application of nanotechnology to agriculture, having gained the first ever US EPA and Canadian PMRA approvals for the use of nanomaterials as delivery systems in crop protection. Vive is one of Canada and North America's fastest growing companies and one of Canada's fastest growing clean tech companies.



Fahad Razak, Co-Lead, GEMINI

Fahad Razak is an internist at St Michael's Hospital (Unity Health Toronto), Associate Professor and Canada Research Chair in Data-Informed Health Care Improvement at the University of Toronto, Provincial Lead for Quality Improvement in General Medicine at Ontario Health, and Vice President Research at the Canadian Society of Internal Medicine. He co- founded GEMINI, the largest hospital research and quality improvement network in Canada, and has received over \$80 million in grant funding as Principal Investigator. GEMINI is used by an active community of more than 1000 scientists, health system leaders. Razak completed a degree in Engineering Science and Medical Doctorate at the University of Toronto and was the first physician appointed as the David E. Bell Fellow at Harvard University. He is a Senior Fellow at Massey College and on the advisory board of the BMJ. Notable recognitions include the inaugural Canadian Society for Internal Medicine National Award for Mentorship, Dean's Emerging Leader Award and the President's Impact Award at the University of Toronto; the Canadian Society of Internal Medicine's New Investigator Award; and the Graham Farquharson Knowledge Translation Fellowship from the PSI Foundation. Razak served as Scientific Director for the Ontario COVID-19 Science Advisory Table and contributed to over 50 science and policy briefs that shaped Ontario's response to the pandemic. He was a member of the Federal Expert Panel on Science Advisory and Research convened by the Minister of Health, and the on the Transformation Sub-Committee convened by the Board of the Canadian Institute for Health Information to help guide their future directions.

3:15- 3:30pm | Afternoon Break

3:30-4:30pm | Panel 5 – Preparing for Precision Medicine



Moderator: Carolyn Cummins, Associate Scientific Director, Precision Medicine Initiative (PRiME)

Carolyn Cummins is an Associate Professor and Director of the Pharmaceutical Sciences graduate program in the Leslie Dan Faculty of Pharmacy at the University of Toronto. She is also the Associate Scientific Director of the Next Generation Precision Medicine Initiative (PRiME). PRiME is an institutional strategic initiative at the University of Toronto, dedicated to addressing unmet needs and challenges in drug discovery, diagnostics, and disease biology. PRiME



brings together a powerful continuum of world-class basic and clinical scientists, biomedical engineers, innovators, and entrepreneurs, fostering seamless collaborations with Toronto's precision medicine ecosystem and global partners.

Cummins received her PhD in pharmaceutical chemistry from the University of California San Francisco and obtained molecular biology and in vivo pharmacology experience during her post-doctoral fellowship at UT Southwestern in Dallas. Her research program focuses on the study of nuclear hormone receptors with emphasis on drug target validation and early drug discovery. With expertise in pharmacokinetics, analytical chemistry, cell and molecular biology, and small animal physiology, her group is exploring the use of novel small molecules to treat obesity and fatty liver disease.

Cummins has co-authored over 85 research publications and 3 patents (h-index: 46). She has held over \$6M in grant funding from Canadian funding agencies CIHR, IDRC, HSFC and NSERC. She is passionate about promoting translation of academic discoveries to practice and is helping to grow PRiME as a community hub and knowledge broker that promotes innovations in early drug discovery and precision medicine.



Ben Hedley, Hematology Scientist, Pathology and Laboratory Medicine, London Health Sciences Centre (LHSC)

Ben Hedley was born in the United Kingdom and educated in Belgium, the United Kingdom and Canada. He is currently a Medical Scientist within LHSC in London Ontario Canada. In the department of Pathology and Laboratory Medicine, he is in the division of hematology. Ben currently sits on the College of American Pathologists Diagnostic Immunology and Flow Cytometry Committee, involved with the Clinical and Laboratory Standards Institute (CLSI). He is also a board member for the International Council on Standardization of Hematology (ICSH). His interests have been primarily on furthering the standardization of laboratory testing, whether standardization through guidelines or products that aid in elevating the base level of laboratory knowledge higher for all the laboratories that perform testing. Some of these have been as part of the ICSH and also through CLSI guideline development. Ben feels very fortunate to have been given the opportunity to work on this because with current regulations evolving, he believes this will form the basis for some of the regulations that will come. Most recently, he has started a collaboration with a group to perform artificial intelligent analysis.



Don Husereau, Adjunct Professor, University of Ottawa

Don Husereau is an Adjunct Professor of Medicine at The University of Ottawa. He does freelance health care research and works with private and public sector life sciences organizations to help them understand the value of health technology and its implications for health and innovation policy. In Canada, he has served on National and Provincial Expert Committees for healthcare reimbursement decisions and has been an invited expert member of a federal commission focused on innovation policy as well as an advisor to the Federal drug prices regulator. He is also currently a Senior Associate at the Institute of Health Economics.



Lincoln Stein, Scientific Director (interim) & Head Adaptive Oncology, Ontario Institute for Cancer Research (OICR)

Lincoln Stein is an MD/PhD who works on biological data integration and visualization. After his training at Harvard Medical School, where he became a board-certified pathologist, he worked at the Whitehead Institute/MIT Center for Genome Research developing databases used for the mouse and human genome maps. From 1998-2008 he worked at Cold Spring Harbor Laboratory on



a variety of genome-scale databases including WormBase, the database of the *C. elegans* genome, Gramene, a comparative genome mapping database for rice and other monocots, the International HapMap Project Database, and a human biological pathways database called Reactome. He is now Scientific Director (interim) and Head Adaptive Oncology, at the Ontario Institute for Cancer Research in Toronto, where he works on large-scale genomic data integration projects, including the PanCancer Analysis of Whole Genomes Project, the International Cancer Genome Consortium, and the Terry Fox Marathon of Hope Comprehensive Cancer Centre Network.



Peter Zakarow, Board Chair, DNASTack

Peter is a passionate entrepreneur and business leader. Over 25 years he has launched multiple successful innovation companies and is a trusted CEO advisor to a wide array of global companies, including IBM, Deloitte, Google, SAP, VMware, and Wipro, as well as many political leaders. He has helped launch and grow numerous rapidly growing innovation-focused businesses tackling major industries: including ThoughtWire (Digital Twin for health care and smart buildings), Alexynn Strategy (CEO advisory services focused on creatively unlocking business intelligence), DNASTack (genomics and health federated data enablement), Keel Digital (integrated mental health, telehealth, and lab services solutions), Tom&Sawyer (market leading gently-cooked pet meals) and Animetric.AI (precision pet health data platform). His primary focus is to leverage data and innovation in ways to dramatically improve health outcomes for our family members, both human and pet. Peter also has extensive Board experience across a wide range of private and public organizations, contributing his governance expertise, objective strategic insights and mentorship to top executive teams across technology, health care, sport's governing bodies, government tribunals, and global retailers.

4:30-4:50pm | Government Remarks: Hon. Victor Fedeli, Minister of Economic Development, Job Creation and Trade



Minister Victor Fedeli (Nipissing), Minister of Economic Development, Job Creation and Trade, Progressive Conservative Party of Ontario

The Honourable Victor Fedeli is a lifelong entrepreneur, successful businessperson, author, and philanthropist, and serves the Ford government as Minister of Economic Development, Job Creation and Trade. His business experience led his firm Fedeli Corporation to be ranked 34th in the Top 50 Best Places to Work in Canada in 1989. It also served him well, when he was elected to two terms as Mayor of North Bay from 2003 to 2010. As Mayor, Vic focused on fiscal prudence and economic development, restoring hope and restoring solvency to North Bay. In 2011 Vic was elected to the Ontario Legislature and is now serving his fourth term as MPP for Nipissing. In 2018 the PC Caucus unanimously elected him to serve as Interim Leader of the Official Opposition. Vic served ten terms on the Board of the North Bay and District Chamber of Commerce, served as Director with Global Vision, and has served on many agencies, boards, and commissions, often as Chair. He is married to local humor writer, Patty, and is always seen in one of his trademark yellow ties.

4:50-5:00pm | Close the Day & Next Steps

5:00 - 6:00pm | Networking Reception